ArticleAnnals of hematology2026

Comparable outcomes of BTK inhibitors and fixed-duration venetoclax plus rituximab in second-line treatment of chronic lymphocytic leukaemia: a real-world analysis by the Czech CLL study group.

Jana Mihályová et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.